Bio-Optronics Builds Oncology-Specific Features into CTMS
Bio-Optronics has built oncology-specific function into its CTMS, Clinical Conductor
Bio-Optronics has built oncology-specific function into its CTMS, Clinical Conductor. These features include adaptive and dynamic protocol design; billing compliance function that allows organizations managing and executing oncology studies to create multiple versions of cost-allocation grids for multi-arm trials, providing more accurate billing information with less time and effort; and financial tools to accommodate complex and changing protocols, allowing organizations to effectively bill for recurring visits and other complexities that result from oncology protocol design. In addition to this, organizations can set specific Medicare coverage designations at specific sites.Finally, the CTMS contains National Cancer Institute reporting functionality that creates NCI-compliant reports and allows researchers to adhere to NCI grant requirements more easily.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
